Adicet Bio (ACET)

• Market cap: $74.9M
• 1 day: -1.22%
• 5 days: 0.79%
• 1 month: -4.92%
• 3 months: -38.62%
• 6 months: -30.66%
• Year to date: -6.72%
• 1 year: -66.85%
• 5 years: -94.10%
• 10 years: -94.10%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 143

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

4% more capital invested

Capital invested by funds: $78.8M [Q2] → $81.8M (+$2.98M) [Q3]

10.3% less ownership

Funds ownership: 79.21% [Q2] → 68.9% (-10.3%) [Q3]

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

28% less funds holding

Funds holding: 87 [Q2] → 63 (-24) [Q3]

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K

77% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 30